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Abstract
Background: N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is a synthetic retinoid with potent pro-apoptotic
activity against several types of cancer, but little is known regarding mechanisms leading to chemoresistance.
Ceramide and, more recently, other sphingolipid species (e.g., dihydroceramide and dihydrosphingosine) have
been implicated in 4-HPR-mediated tumor cell death. Because sphingolipid metabolism has been reported to be
altered in drug-resistant tumor cells, we studied the implication of sphingolipids in acquired resistance to 4-HPR
based on an acute lymphoblastic leukemia model.
Methods: CCRF-CEM cell lines resistant to 4-HPR were obtained by gradual selection. Endogenous sphingolipid
profiles and in situ enzymatic activities were determined by LC/MS, and resistance to 4-HPR or to alternative
treatments was measured using the XTT viability assay and annexin V-FITC/propidium iodide labeling.
Results: No major crossresistance was observed against other antitumoral compounds (i.e. paclitaxel, cisplatin,
doxorubicin hydrochloride) or agents (i.e. ultra violet C, hydrogen peroxide) also described as sphingolipid
modulators. CCRF-CEM cell lines resistant to 4-HPR exhibited a distinctive endogenous sphingolipid profile that
correlated with inhibition of dihydroceramide desaturase. Cells maintained acquired resistance to 4-HPR after the
removal of 4-HPR though the sphingolipid profile returned to control levels. On the other hand, combined
treatment with sphingosine kinase inhibitors (unnatural (dihydro)sphingosines ((dh)Sph)) and glucosylceramide
synthase inhibitor (PPMP) in the presence or absence of 4-HPR increased cellular (dh)Sph (but not ceramide) levels
and were highly toxic for both parental and resistant cells.
Conclusions: In the leukemia model, acquired resistance to 4-HPR is selective and persists in the absence of
sphingolipid profile alteration. Therapeutically, the data demonstrate that alternative sphingolipid-modulating
antitumoral strategies are suitable for both 4-HPR-resistant and sensitive leukemia cells. Thus, whereas sphingolipids
may not be critical for maintaining resistance to 4-HPR, manipulation of cytotoxic sphingolipids should be
considered a viable approach for overcoming resistance.
Background
The synthetic retinoid 4-HPR has potential as a promis-
ing chemotherapeutic drug due to its strong pro-apop-
totic effect on a variety of tumors, especially on acute
lymphoblastic leukemia (ALL) cell lines [1,2]. Thus, 4-
HPR is currently being applied in several clinical trials
against different tumors [3,4] and has been shown to
overcome tumor resistance to ATRA [5]. However,
studies in human ovarian carcinoma cell lines [6-8] have
shown that resistance to 4-HPR may also develop. Resis-
tance (intrinsic or acquired) to the chemotherapeutic
drug remains the main source of failure in current che-
motherapeutic treatments [9]. Acquired resistance is an
especially complicated problem due to the fact that
tumors often not only become resistant to the drug they
were treated with, but also to other drugs (multidrug
resistance (MDR) phenotype). Thus, determining resis-
tance-related molecular mechanisms is crucial for
improving treatment effectiveness.
4-HPR is a well-studied antitumor agent with a
mechanism of action that has been linked to oxidative
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any medium, provided the original work is properly cited.stress induction [2,10,11], as well as to modifications of
endogenous sphingolipid (SL) levels [1,8,12,13]. Regard-
ing 4-HPR resistance, studies mentioned above revealed
SL profiles as one of the main distinguishing character-
istics between 4-HPR-sensitive and 4-HPR-resistant
ovarian carcinoma cell lines.
Sphingolipids are lipids based on sphinganine or
sphingosine that form a large family of molecules with
both structural and signaling functions [14]. According
to Prinetti et al. [7] and Maurer et al. [15], 4-HPR
increases endogenous ceramide (Cer) levels but
induces lower or no Cer accumulation in resistant can-
cer cells. Combination of 4-HPR with modulators of
ceramide metabolism (e.g., inhibitors of Cer conversion
into Sph1P or into glucosylceramides) has been pro-
posed as an alternative to increase 4-HPR mediated
cytotoxicity [1,8,15,16] or to overcome 4-HPR resis-
tance in ovarian carcinoma models [8,15,17]. On the
other hand, glucosylceramide synthase (GCS) activity
has been linked to MDR phenotype and P-gp expres-
sion [18], suggesting positive feedback among ceramide
glucosylation and MDR development. In addition,
recent data show accumulation of dihydroceramide
(dhCer), and not Cer, upon 4-HPR treatment [8,19].
DhCer was thought for a long time to be the inactive
precursor of Cer [20], and is now being implicated in
several biological processes, including cell cycle arrest
[19] and autophagy [21].
Focusing on the MDR phenotype, no cross-resistance
to other natural or synthetic retinoids have been
observed in 4-HPR-resistant A2780 cells [6]. Cross-resis-
tance to other SL modulating agents has not been
tested. This study is the first to evaluate acquired 4-
HPR resistance in ALL and is an in depth analysis of
the role of SLs in the 4-HPR-resistance phenotype. The
results show that dhCer accumulation, as well as other
changes in SL profiles, are reversible phenomena that
may be independent of the acquired resistance. Regard-
ing therapeutics, the data reveal that 4-HPR resistance
in ALL cells does not follow the MDR phenotype.
Furthermore, resistance to this synthetic retinoid can be
overcome by manipulating levels of cytotoxic SLs, creat-
ing opportunities for other alternative treatments.
Methods
Reagents
RPMI 1640 (#11835-034), red phenol free RPMI 1640
(#11835-063), and heat inactivated fetal bovine serum
(FBS) (#10082-174) were purchased from Gibco/BRL
(Invitrogen). L-glutamine (#G7513), propidium iodide
(PI), 5-bromo-2-deoxyuridine (BrdU), 4-(hydroxyphenyl)
retinamide (4-HPR), d,l-threo-1-phenyl-2-palmitoyla-
mino-3-morpholino-1-propanol (PPMP), d,l-threo-dihy-
drosphingosine (DHS), 4-[[4-(4-chlorophenyl)-2-
thiazolyl]amino]phenol (SKI-II), paclitaxel, doxorubicin
hydrochloride (Adriamycin
® hydrochloride), cis-diammi-
neplatinum(II) dichloride (cisplatin), and H2O2 were
purchased in Sigma Chemical Co. L-threo-dihydrosphin-
gosine (safingol), D-erythro-sphinganine (C17 base)
(C17-dhSph), and D-erythro-sphingosine (C17 base)
(C17-Sph) were purchased from Avanti Polar Lipids,
Inc. The cell viability XTT assay kit (#11465015001) was
purchased from Roche Molecular Biochemicals and
Annexin V-FITC Apoptosis Detection Kit from Calbio-
chem
®.D - erythro-2-N-[12_-(1_-D-erythro-2-N-[12_-(1_-
pyridinium)dodecanoyl]-4,5-dihydrosphingosinebromide
(D-erythro-C12-dihydroceramide; C12-PyrdhCer) was
synthesized by the Lipidomics Core Facility at the Medi-
cal University of South Carolina [22]. Anti-BrdU-FITC
(#347583) was purchased from Becton Dickinson and
carboxyfluorescein diacetate succimidyl ester (CFSE;
#C34554) from Molecular Probes.
Cells were exposed to a final DMSO concentration of
≤ 0.1%.
Cell lines and culture conditions
Human CCRF-CEM and Jurkat acute lymphoblastic leu-
kemia cells were purchased from ATCC and cultured in
RPMI 1640 with 2 mM L-glutamine supplemented with
10% heat inactivated FBS (complete culture medium).
Cells were kept at 37°C in a humidified incubator con-
taining 5% CO2. To develop 4-HPR-resistant cells,
CCRF-CEM cells were continuously exposed to increas-
ing 4-HPR concentrations, starting from 0.5 μMa n du p
to 10 μM. 4-HPR-containing complete culture medium
was replaced every 48-72 h and cells seeded at 0.4 × 10
6
cells/ml. Cells were exposed to a higher 4-HPR concen-
tration when death in cell culture was < 20% according
to trypan blue exclusion.
Treatment preparation
4-HPR (#H7779) was dissolved in DMSO to 10 mM, ali-
quoted, and stored at -80°C. PPMP (#P4191; 1:1 etha-
nol/H2O, 20 mM stock), DHS (#D7033; DMSO/ethanol,
15 mM stock), safingol (#860488P; ethanol 95%, 10 mM
stock), SKI-II (#S5696; DMSO, 50 mM stock), paclitaxel
(#T7191; DMSO, 10 mM stock), and doxorubicin hydro-
chloride (#D1515; DMSO, 20 mM stock) were stored at
-20°C. Cisplatin (#P4394) and H2O2 (#H1009) solution
were prepared fresh for each experiment. Cisplatin was
prepared by dissolving in H2O, vortexing 1 min, and
shaking for 10 min, followed by incubation at 37°C for
15 min, vortexing, and adding more H2O to a final con-
centration of 400 μg/ml. For ultraviolet (UV) radiation,
we used a GS Gene Linker UV chamber (Bio-Rad),
which emits UVC light (lavg =2 5 4n m )a ts e l e c t e d
doses of 1, 3, or 5 mJ/cm
2. For UV radiation, cells were
plated in 60-mm dishes (approximately 500,000 cells/ml;
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6 cells/sample) in red phenol-free culture
medium.
Cell viability
Standard XTT assay was used to determine cell viability by
means of metabolic activity [23]. Cells were plated in 96-
well plates at 750,000 cells/ml and 100 μl/well. After 4 h,
treatments were added as 50 μl/well with a final density of
500,000 cells/ml and final volume of 150 μl/well. Four
replicates were used per experimental condition, and all
compounds were added at the same time. The XTT
reagent mixture was added 4 h before the selected end-
point and absorbance at 490 nm determined for each well
according to the manufacturer’si n s t r u c t i o n s .C u l t u r e
media plus XTT reagent was used as the control and the
effect of treatments calculated as the absorbance value
percentage of corresponding control cells. A slightly modi-
fied protocol was used for simultaneous analysis of viabi-
lity and SL profile by LC/MS and for ultraviolet radiation
(UV) treatment. Briefly, cells (approximately 500,000 cells/
ml; 5 × 10
6 cells/sample) were seeded on 60-mm culture
dishes and treatment added after 4 h. For viability studies,
aliquots of cells were taken from the 60-mm dish cultures
and placed in 96-well plates. Any remaining cells were col-
lected for LC-MS analysis when required. Red phenol-free
culture medium was used for UV treatment.
Cell proliferation (BrdU labeling)
Cells (2 ml/well, 10
6 cells/ml) were seeded in 6-well
plates in complete culture medium. After 4 h, BrdU
(#B5002; 10 μM final concentration) was added to the
medium and the cells incubated for 3 h at 37°C and 5%
CO2. Cells were washed twice with 1% BSA/PBS and re-
suspended in 200 μlc o l dP B S .C e l l sw e r ef i x e dw i t h
cold 70% ethanol (vortex gently, incubate for 30 min on
ice), centrifuged (10 min, 500 g, room temperature), and
the pellets vortexed gently and re-suspended in 1 ml 2N
HCl/0.5% Triton X-100 (30 min incubation at room
temperature) to denature the DNA. After 30 min, cells
were centrifuged (10 min, 500 g) and 1 ml
Na2B4O7·10H2O (pH 8.5) added to the pellets. Samples
were centrifuged again and the pellets re-suspended in 1
ml 0.5% Tween20 in 1% BSA/PBS. Anti-BrdU-FITC (20
μl) was added to each sample (10
6 cells) and incubated
for 30 min at room temperature. After discharging anti-
body, cells were washed once with 0.5% Tween20 in 1%
BSA/PBS, centrifuged, and the pellets re-suspended in 1
ml PBS containing 5 μg/ml PI (#P4170). Cells were
incubated for 30 min at room temperature with PI
before flow cytometric analysis. Proliferation was esti-
mated as the percent of FITC-positive cells with 2C
(G0/G1) to 4C (G2/M) DNA content and graphically
represented as the percent of FITC-positive cells relative
to the CCRF-CEM cell line.
Apoptotic cell death
Apoptotic cell death was analyzed in order to establish
cellular sensitivity/resistance to 4-HPR. Cells were trea-
ted and cell death determined by annexin V-FITC and PI
staining using the Annexin V-FITC Apoptosis Detection
Kit (PF032) according to the manufacturer’s instructions.
Flow cytometric analysis of apoptotic cell death was per-
formed using a Beckman Coulter Gallios cytometer in
the General Research Services SGIker of the UPV/EHU
(http://www.ikerkuntza.ehu.es/p273-sgikerhm/en/).
LC/MS analysis of endogenous sphingolipid species
Cells were seeded and treated in 60-mm culture dishes
as described above. After the selected treatment time,
cells were washed twice with PBS to avoid external SL
contamination from media and further analysis per-
formed by the Lipidomics Core Facility of the Medical
University of South Carolina (http://www.musc.edu/
BCMB/lipidomics/index.shtml) as described previously
[22,24]. Total values were normalized to endogenous
inorganic phosphates (Pi) using adapted Bligh and Dyer
lipid extraction [25].
In situ dihydroceramide desaturase assay
C12-PyrdhCer was used as a substrate for the dihydro-
ceramide desaturase enzyme. The synthetic analogue
was dissolved in 100% ethanol at a stock concentration
of 100 mM and stored at -20°C, protected from light.
Aliquots of the stock solution were diluted and added to
cells in complete culture medium. The final C12-Pyrdh-
Cer concentration in medium was 500 nM. When
required, C12-PyrdhCer was added together with 4-HPR
and incubated for the selected time points. Levels of
C12-PyrdhCer and its product (C12-PyrCer) were ana-
lyzed by LC/MS as described previously [22,24].
In situ estimation of dihydrosphingosine and sphingosine
utilization
Estimation was determined by the utilization of unna-
tural dihydrosphingosine (C17-dhSph; #860654P) or
sphingosine (C17-Sph; #860640P) species as previously
described by Spassieva et al. [26]. Cells were seeded and
treated in 60-mm culture dishes as described above and
C17-dhSph or C17-Sph (500 nM final concentration; 10
mM stock solution in ethanol, -20°C) incubated for 30
min prior to ending the defined treatment. Cells were
collected on ice, washed with cold PBS, and analyzed by
LC/MS. Data were normalized to Pi content and calcu-
lated as the percent of product (selected C17 species) in
relation to total C17 species in the cell.
Statistical analysis
Results are expressed as the mean ± standard deviation
(SD). The number of replicates is specified for each
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data (Kolmogorov-Smirnoff test) was determined using
analysis of variance (ANOVA) plus Bonferroni or Tam-
hane post-hoc tests for multiple comparisons. Bonfer-
roni or Tamhane was chosen based on the equality of
variance in samples (Levene’s test). The Kruskal Wallis
test with Mann-Whitney test for pair-wise comparison
was used for data that was not normally distributed
(SPSS, version 15.0). Significance was set at P <0 . 0 5o r
P < 0.01 as specified for each figure.
Results
Continuous exposure to increasing 4-HPR concentrations
leads to acquired drug resistance phenotype
Resistance in 4-HPR-resistant CCRF-CEM cell lines (R
cell lines) was determined by XTT assay upon exposure
to the drug for 48 h. R cell lines selected at fixed con-
centrations of 4-HPR (R0.5, R3, R5, and R10) became
fully resistant to the corresponding 4-HPR concentra-
tions (i.e. 0.5 μM, 3 μM, 5 μMa n d1 0μM; Figure 1A).
Moreover, R cell lines developed partial (R0.5) or full
(R3, R5) resistance to 4-HPR concentrations up to 10
μM. Thus, we were able to develop cell lines resistant to
various concentrations of 4-HPR.
Interestingly, all R cell lines had a significantly lower
proliferation rate than parental CCRF-CEM cells (P <
0.05) without significant differences among R cell lines
based on BrdU incorporation rate (Figure 1B). These
results indicate changes not only in cell survival, but
also cell cycle progression.
Acquired resistance against 4-HPR does not fulfill
multidrug-resistance phenotype
4-HPR-sensitive parental leukemia cell line (CCRF-
CEM) and 4-HPR-resistant cell lines (R0.5 and R10)
were challenged by different anticancer drugs, such as
cisplatin (0.5, 1, 2.5, or 5 μg/ml), paclitaxel (1, 5, 10, 30,
or 100 nM), or adriamycin (50, 100, or 500 nM) and
other insults such as UV irradiation (1, 3, or 5 mJ/cm
2)
or direct oxidative stress (H2O2; 10, 50, or 100 μM).
Based on metabolic activity, cell variability was analyzed
after 48 h to determine the endpoint comparative cyto-
toxicity. Figure 2 summarizes the results obtained with
the selected concentrations. No significant major cross-
resistance was observed against any of the mentioned
agents, and cytotoxicity was directly correlated to the
concentration of the drugs. Nevertheless, compared to
parental CCRF-CEM cells, R0.5 and R10 cell lines were
significantly more resistant to H2O2 (P <0 . 0 5 ) . Interest-
ingly, R0.5 cells exhibited slightly increased sensitivity to
UV, and R10 cells exhibited significantly increased sensi-
tivity to UV (P < 0.05). Dose-dependent minor differ-
ences are detailed in Figure 2.
The sphingolipid profile in R cell lines reflects prolonged
inhibition of DES
LC-MS mediated analysis of the endogenous SL species
revealed a clear dose-dependent accumulation of total
dhCer and decreased levels of total endogenous Cer in
R cell lines compared to parental CCRF-CEM cells
(Figure 3A). Also, dhSph (upstream of dhCer on the
de novo SL synthesis pathway) showed a dose-depen-
dent tendency for accumulation in R cell lines (Figure
3B), whereas values for SL species downstream of Cer
(e.g., GluCer and LactCer) were significantly decreased
(Figure 3C). These data indicate the accumulation of
SL species upstream of dihydroceramide desaturase
(DES) activity and decreased SL species downstream of
DES activity. Thus, the activity of the enzyme was ana-
lyzed next (Figure 4). Cellular DES activity was mea-
sured by means of the intracellular desaturation of a
synthetic dhCer analog (C12-Pyr-dhCer conversion
into C12-Pyr-Cer). Similar to what was observed in
CCRF-CEM cells upon acute 4-HPR treatment (1-2 h
with 5 μM 4-HPR), DES activity was inhibited in all R
cell lines (CCRF-CEM vs.R 0 . 5 ,R 3 ,R 5 ,R 1 0c e l ll i n e s ,
P < 0.01). No significant differences were observed in
the level of inhibition among R3, R5, and R10 cells,
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Figure 1 Acquired resistance upon long-term 4-HPR exposure.
(A, left) R cell lines were continuously exposed to different 4-HPR
concentrations (0.5, 3, 5, and 10 μM; cell lines named R0.5, R3, R5,
and R10, respectively) and resistance verified by comparison to 48 h
drug-withdrawn R cells. Data are the average ± SD of three
independent experiments performed in quadruplicates, n = 12. (A,
right) Parental CCRF-CEM cells and developed R cell lines were
exposed to 10 μM 4-HPR and viability estimated after 48 h of drug
exposure. (n = 12). **P < 0.01; ANOVA plus Tamhane post-hoc
analysis. (B) Comparative cell proliferation was determined by BrdU
labeling as specified in Materials and Methods. Data are average ±
SD of four independent experiments. *P < 0.05; Kruskal Wallis and
Mann-Whitney test for pair-wise comparison.
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activity compared to the other R cell lines (R0.5 vs.R 3 ,
R5, R10; P < 0.01; Figure 4). Notably, acute treatment
of CCRF-CEM cells with 4-HPR (5 μM) induced nearly
complete inhibition of DES in situ activity within the
first hour (conversion rate (%) of 13.00 ± 0.45 in con-
trol vs. 0.61 ± 0.03 in 4-HPR-treated CCRF-CEM
cells). On the other hand, resistant cells under con-
stant 5 μM 4-HPR exposure (R5 cells) showed a some-
what higher desaturation rate than 5 μM4 - H P R -
treated parental CCRF-CEM cells (conversion rate (%)
of 0.61 ± 0.17 vs.2 . 0 9±0 . 2 0a t2h ) ,w h i c hs u g g e s t s
slight adaptation.
Withdrawal from 4-HPR exposure reverses endogenous SL
levels without substantially affecting cell resistance
In order to study the reversibility of drug resistance, we
removed R10 cells from 4-HPR exposure for either 48 h
or long-term (average of 8 passages or 3 weeks) and SL
levels analyzed (Figure 5A-C). Resistance was measured
simultaneously by annexin V-FITC/PI staining and XTT
by challenging drug-withdrawn R10 cells with specific 4-
HPR concentrations (Figure 6). Forty-eight hours was
enough to alter the endogenous SL profile, resulting in a
significant decrease in dhCer levels (Figure 5A) and
increased intracellular GluCer (Figure 5C) (R10 vs. R10
48 h WD, P < 0.05). Moreover, endogenous dhCer (Fig-
ure 5A) and LactCer (Figure 5C) levels after 48 h with-
out 4-HPR were comparable to those obtained in the
parental CCRF-CEM cell lines (CCRF-CEM vs. R10 48
hW D ;P > 0.05). The decrease in dhSph and dhCer
levels, as well as the increase in SL species downstream
of DES activity (e.g., Cer, GluCer and LactCer), were
sustained after long-term absence of 4-HPR in R10 cells
(R10 vs. R10 long WD; P <0 . 0 5 )w i t ha l lS Lv a l u e s
except GluCer being similar to the values in the parental
cell line (R10 long WD vs. CCRF-CEM; P > 0.05). How-
ever, removal of the drug did not reverse the acquired
resistance phenotype compared to parental CCRF-CEM
cells (Figure 6; CCRF-CEM < R10 48 h WD or CCRF-
CEM < R10 long WD; P < 0.01), though it did partially
affect metabolic activity compared to R10 cell line (R10
> R10 48 h WD or R10 > R10 long WD; P <0 . 0 5o rP
< 0.01 as specified in Figure 6B). Interestingly enough,
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Figure 2 Effect of selected insults on the viability of 4-HPR-sensitive and resistant leukemia cell lines. 4-HPR-sensitive (CCRF-CEM) and
derived resistant cell lines (R0.5 and R10) were exposed to several drugs or UV radiation, and cytotoxicity tested after 48 h by the XTT assay.
Data are average ± SD of three independent experiments performed in quadruplicates (n = 12); *P < 0.05, **P < 0.01; ANOVA plus Tamhane
post-hoc test.
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Figure 3 Comparative endogenous SL pattern in 4-HPR-
sensitive and resistant leukemia cell lines. Cell were grown with
(R cell lines) or without (CCRF-CEM) 4-HPR. Endogenous TOTAL (sum
of the different fatty acid chain-length species) dhCer (A, left panel)
and Cer (A, right panel) levels, as well as dhSph (B), TOTAL GluCer,
and LactCer (C) levels were determined by LC/MS. Data are average
± SD of four (A, B) or two (C) independent experiments. *P < 0.05;
**P < 0.01; ANOVA plus Tamhane or Bonferroni post-hoc test.
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Figure 5 Comparative SL profile analysis upon drug
withdrawal. R10 cells were incubated in 4-HPR-free medium for 48
h (WD = without drug) or long-term (~3 weeks) and endogenous
SL profiles analyzed by LC-MS. Significance was based on R10
values. Data are average ± SD of 2-4 independent values. *P < 0.05;
**P < 0.01; ANOVA plus Tamhane or Bonferroni post-hoc test.
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Figure 4 Comparative analysis of dihydroceramide desaturase (DES) activity. Cells were incubated with the unnatural pyridinium dhCer
(C12-PyrdhCer) alone or with 4-HPR (5 μM) for the selected time points and conversion into C12-PyrCer measured by LC/MS. Data are average ±
SD of two independent values. **P < 0.01; ANOVA plus Bonferroni post-hoc test.
Apraiz et al. BMC Cancer 2011, 11:477
http://www.biomedcentral.com/1471-2407/11/477
Page 6 of 13long-term withdrawal of the drug (R10 long WD)
induced not just a recovery of parental (CCRF-CEM) SL
levels, but also a recovery of the proliferation rate (addi-
tional file 1).
Sphingolipid modulators as an alternative treatment
against 4-HPR-sensitive and resistant leukemia cells
We have demonstrated that, in resistant leukemia cells,
the observed changes in SLs are reversible events
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Figure 6 Effect of drug withdrawal on cell resistance. (A) Parental sensitive CCRF-CEM cells, resistant R10, and long-term drug withdrawn
resistant (R10 longWD) cells were treated and cell death determined by annexin V-FITC/propidium iodide staining at the selected time points.
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Apraiz et al. BMC Cancer 2011, 11:477
http://www.biomedcentral.com/1471-2407/11/477
Page 7 of 13distinct from the acquired resistance phenotype. At this
point we wanted to address whether increased pro-
apoptotic SLs (e.g., Cer [27]) and/or decreased pro-sur-
vival species (e.g., dhSph-1P, Sph-1P [27,28]) could
enhance 4-HPR-mediated cytotoxicity. First, we studied
the changes in phosphorylated SLs upon 4-HPR treat-
ment in parental CCRF-CEM cells. 4-HPR induced a
clear increase in dhSph, dhCer, and phosphorylated (dh)
Sph species (Figure 7A).
Accumulation in (dh)Sph-1P was likely due to
increased (dh)Sph kinase (SK) activity. This possibility
was evaluated using 17C-dhSph as a cellular probe to
evaluate the activity of sphingosine kinases (Figure 7B,
C). One hour pre-treatment with 4-HPR resulted in a 2-
fold increase in 17C-dhSph phosphorylation (Figure 7B)
and decreased Cer production (17C-Cer) (Figure 7C).
Thus, 4-HPR induced flux through sphingosine kinase.
Next, we studied the formation of phosphorylated
sphingosine species in 4-HPR-sensitive (CCRF-CEM)
and resistant (R0.5-R10) cell lines. After 30 min incuba-
tion with 17C-dhSph and 17C-Sph, a clear increase in
phosphorylation in resistant cells was observed com-
pared to parental CCRF-CEM cells (Figure 7D). The
amount of phosphorylation was proportional to the
degree of resistance. Analysis of endogenous SLs
confirmed accumulation in dhSph-1P and Sph-1P (Fig-
ure 7E). Therefore, 4-HPR resistance is accompanied by
increased activity of (or at least flux through) sphingo-
sine kinase.
Based on the observed decrease in pro-apoptotic Cer
levels and increased pro-survival (dh)Sph-1P levels, we
combined 4-HPR with PPMP (GCS inhibitor) and the
unnatural dhSph, d,l-threo-dhSph (DHS; competitive
inhibitor of (dh)Sph kinase). The data revealed that, in
the parental cell line (CCRF-CEM), the combination of
4-HPR with 5 μMD H So r≥ 5 μM PPMP increased 4-
HPR (1 μM)-mediated cytotoxicity with 24 h exposure
(P < 0.01; additional file 2A-B). The combination of
both SL modulators significantly increased the effects of
each agent alone (P < 0.01). Thus, a mixture of both SL
modulators with 1 μM 4-HPR (complex DHS treatment)
resulted in the highest toxicity in parental cells (addi-
tional file 2; viability PPMP+DHS (58.91 ± 7.54) vs.
PPMP+DHS+4-HPR (22.29 ± 16.81); P <0 . 0 1 ) .I n t e r e s t -
ingly, DHS-based treatment induced cytotoxicity not
just in 4-HPR-sensitive cells (CCRF-CEM), but also in
4-HPR-resistant cells (R0.5, R5, R10; Figure 8A). Substi-
tution of d,l-threo-dhSph (DHS) by l-threo-dhSph (safin-
gol) increased the cytotoxic response to combined
therapy (PPMP+DHS+4-HPR vs. PPMP+SAF+4-HPR),
0
1
2
3
4
5
6
p
m
o
l
/
n
m
o
l
P
i
No treatment
4-HPR 10PM
dhSph dhSph-1P dhCer Cer Sph Sph-1P
A
B
0,0
0,5
1,0
1,5
2,0
2,5
17C-dhSph-1P
%
 
o
f
 
t
o
t
a
l
 
1
7
C
 
s
p
e
c
i
e
s No treatment
4-HPR 10PM (1h)
0
20
40
60
80
100
17C-dhSph TOTAL 17C-dhCer TOTAL 17C-Cer
%
 
o
f
 
t
o
t
a
l
 
1
7
C
 
s
p
e
c
i
e
s No treatment
4-HPR 10PM (1h)
D
0
1
2
3
4
5
6
7
17C-dhSph-1P 17C-Sph-1P
%
 
o
f
 
t
o
t
a
l
 
1
7
C
 
s
p
e
c
i
e
s
CCRF-CEM
R0.5
R10
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
4,0
4,5
dhSphd h S ph-1P SphS ph-1P
p
m
o
l
/
n
m
o
l
P
i
CCRF-CEM
R0.5
R10
E
C
0
1
2
3
4
5
6
p
m
o
l
/
n
m
o
l
P
i
No treatment
4-HPR 10PM
0
1
2
3
4
5
6
p
m
o
l
/
n
m
o
l
P
i
No treatment
4-HPR 10PM
dhSph dhSph-1P dhCer Cer Sph Sph-1P
A
B
0,0
0,5
1,0
1,5
2,0
2,5
17C-dhSph-1P
%
 
o
f
 
t
o
t
a
l
 
1
7
C
 
s
p
e
c
i
e
s No treatment
4-HPR 10PM (1h)
0,0
0,5
1,0
1,5
2,0
2,5
17C-dhSph-1P
%
 
o
f
 
t
o
t
a
l
 
1
7
C
 
s
p
e
c
i
e
s No treatment
4-HPR 10PM (1h)
0
20
40
60
80
100
17C-dhSph TOTAL 17C-dhCer TOTAL 17C-Cer
%
 
o
f
 
t
o
t
a
l
 
1
7
C
 
s
p
e
c
i
e
s No treatment
4-HPR 10PM (1h)
0
20
40
60
80
100
17C-dhSph TOTAL 17C-dhCer TOTAL 17C-Cer
%
 
o
f
 
t
o
t
a
l
 
1
7
C
 
s
p
e
c
i
e
s No treatment
4-HPR 10PM (1h)
D
0
1
2
3
4
5
6
7
17C-dhSph-1P 17C-Sph-1P
%
 
o
f
 
t
o
t
a
l
 
1
7
C
 
s
p
e
c
i
e
s
CCRF-CEM
R0.5
R10
0
1
2
3
4
5
6
7
17C-dhSph-1P 17C-Sph-1P
%
 
o
f
 
t
o
t
a
l
 
1
7
C
 
s
p
e
c
i
e
s
CCRF-CEM
R0.5
R10
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
4,0
4,5
dhSphd h S ph-1P SphS ph-1P
p
m
o
l
/
n
m
o
l
P
i
CCRF-CEM
R0.5
R10
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
4,0
4,5
dhSphd h S ph-1P SphS ph-1P
p
m
o
l
/
n
m
o
l
P
i
CCRF-CEM
R0.5
R10
E
C
Figure 7 Analysis of 4-HPR-mediated alterations in dhSph and Sph phosphorylation. Externally added unnatural dhSph (17C-dhSph) and
Sph (17C-Sph) analogues were used to estimate the secondary effects of 4-HPR-induced DES inhibition. CCRF-CEM cells were exposed to 4-HPR
(10 μM) for 1 h and unnatural 17C species added for an additional 30 min incubation, as described in Methods. The effect on endogenous SLs
(A) and unnatural dhSph species (B,C) analyzed by LC/MS. Comparative exogenous and endogenous SL profiles among parental (CCRF-CEM) and
resistant cell lines (R0.5, R10) (D, E) were analyzed by the same methodology. Data are average ± SD of an experiment performed in duplicate.
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Page 8 of 13especially in 4-HPR-resistant R5 and R10 cells (P < 0.01;
Figure 8B). Moreover, combination of PPMP with SAF
increased cell toxicity in both 4-HPR-sensitive and resis-
tant cell lines, even in the absence of 4-HPR (PPMP
+DHS vs.P P M P + S A F ;P < 0.01). Notably, SAF concen-
trations > 4 μM were highly toxic (data not shown).
SKI-II, a new generation sphingosine kinase inhibitor,
corroborated the data obtained with DHS or SAF-based
drug combinations (Figure 8C). Therefore, inhibition of
selected pro-survival SL pathways represents an alterna-
tive antitumor strategy, even in the absence of 4-HPR,
and is suitable for both 4-HPR-resistant and sensitive
cells.
LC-MS mediated analysis of SLs in 4-HPR-sensitive cell
lines (CCRF-CEM, Jurkat) revealed that none of the SL
modulators alone or in combination with 4-HPR
increased endogenous total Cer levels (additional file
3A-D). As expected, the GCS inhibitor PPMP decreased
GluCer levels (additional file 4B) and induced a transi-
ent increase in Cer content (additional file 3B). How-
ever, the observed effect on Cer levels was not present
when PPMP was added with other SL modulators (i.e.
combination treatments) (additional file 3D). Unnatural
dhSph species, especially SAF, induced an increase in
both phosphorylated and non-phosphorylated (dh)Sph
species (additional file 5A) and dhCer levels (additional
file 3A), as well as a decrease in GluCer species (addi-
tional file 4A). Changes driven by unnatural dhSph spe-
cies were also observed in response to combination
treatments (additional file 3D, 4C, 5C). Thus, the
selected SL modulators do not act through an early
increase in cellular Cer levels, though the previously
observed cytotoxicity may involve other sphingoids or
later ceramide production.
Discussion
Tumor cell plasticity may easily lead to secondary drug
resistance or the MDR phenotype. 4-HPR, a synthetic
derivative of ATRA, has been shown to exert a potent
antitumoral effect against several types of tumors
[2,12,29]. Nevertheless, resistance to 4-HPR has been
observed in human ovarian carcinoma cell lines [6-8]. In
this study, we developed and characterized resistance in
human ALL cells as an appropriate model due to its
remarkable primary sensitivity to 4-HPR [1,2].
4-HPR has been described to induce accumulation of
endogenous Cer [1,12,13] based on methods that do
not allow differentiation of Cer from its precursor,
dhCer (e.g., [
3H]palmitic acid labeling plus TLC
separation). In a previous study, Prinetti et al. [7]
showed that 4-HPR did not induce Cer accumulation
in 4-HPR-resistant ovarian carcinoma A2780 cells.
Notably, the resistant A2780 cells were developed and
maintained under sustained 4-HPR exposition as in the
leukemia model presented in this study. The current
study demonstrates that 4-HPR exerts similar inhibi-
tion of DES in both acutely treated CCRF-CEM and
long-term treated resistant R cells. Therefore, continu-
ous DES inhibition in R cells induces a clear dose-
dependent accumulation of dhCer and dhSph. Dimin-
ished radioactive (dh)Cer formation upon [
3H]sphingo-
sine labeling and 4-HPR treatment in resistant A2780
carcinoma cells [7] could be interpreted as the inability
of these cells to metabolize externally added [
3H]sphin-
gosine due to the pre-existing accumulation of endo-
genous substrate (dhSph) and product (dhCer) of Cer
synthases. The study in ovarian cells detected a signifi-
cant decrease in LactCer levels, which was also found
in our leukemia model and could be explained by the
sustained DES inhibition.
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Figure 8 Toxicity mediated by the combination of 4-HPR with
SL modulators. Parental-sensitive (CCRF-CEM) and derived-resistant
(R0.5, R5, R10) cells were co-treated with 4-HPR (1 μM), DHS (5 μM;
unnatural dhSph analogue), PPMP (10 μM; glucosylceramide
synthase inhibitor), SAF (4 μM; another unnatural dhSph analogue),
and/or SKI-II (5-20 μM) and cytotoxicity estimated after 48 h
exposure using the XTT assay. Data are average ± SD of at least two
independent experiments performed in quadruplicate (n ≥ 8); **P <
0.01; ANOVA plus Tamhane post-hoc test.
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Page 9 of 13Altered endogenous SL profiles in ALL R cells were
partially reversed after withdrawing 4-HPR for 48 h and
comparable to parental cells after long-term withdrawal.
The recovery of normal SL profiles after drug withdra-
wal did not abolish cell resistance to 4-HPR, as clearly
shown by the classical apoptotic cell death analysis in
Figure 6A, though long-term withdrawal of the drug
slightly altered the metabolic activity of the resistant
cells. These data suggest that despite profound, persis-
tent changes in endogenous SL levels are not required
for the observed resistance in our leukemia model.
Nevertheless, SL roles in the induction or modulation of
initial drug resistance cannot be ruled out.
A reduction in the colony-formation capacity was
observed in resistant A2780 cells [6], and 4-HPR
mediated accumulation of dhCer has been linked to cell
cycle arrest [19]. In the 4-HPR resistant leukemia
model, we found a significant reduction in cell prolifera-
tion with a clear negative correlation between the prolif-
eration rate, DES inhibition level, and consequent dhCer
accumulation. On the other hand, our results show that,
upon drug withdrawal, decreased endogenous dhCer
levels are accompanied by a clear increase in the prolif-
eration rate of resistant cells (additional file 1). In this
regard, the data suggest that endogenous dhCer content
could play a role in regulating the proliferation of resis-
tant cells.
The results of this study also have implications for the
roles of SLs in overcoming resistance to 4-HPR. Combi-
nations of 4-HPR with SL modulators, such as PPMP
(GCS synthase/1-ACS inhibitor) or competitive SK inhi-
bitors (e.g., unnatural threo-dihydrosphingosines DHS/
SAF or sphingosine derivative N,N-dimethylsphingosine)
have been described as an alternative for increasing effi-
cacy of 4-HPR-based treatments [1,8,15,16]. Additional
data support the application of such drug combinations
against drug-resistant cells [8,15]. GCS over-expression
and elevated GluCer levels have been related to drug
resistance in some cancer cells [30,31]. In leukemia,
GCS inhibition has been proposed to reverse resistance
to vincristine and/or doxorubicin [32,33] by a mechan-
ism that is probably linked to intracellular Cer accumu-
lation. In contrast, the current data do not show a close
relationship between 4-HPR resistance and increased
GluCer levels in ALL cells. Both GluCer and LactCer
levels were decreased in R cells compared to parental 4-
HPR-sensitive CCRF-CEM cells. Moreover, recovery of
parental GluCer and LactCer levels did not abolish the
resistant phenotype. Focused on 4-HPR, opposing
results have been reported regarding the toxicity of
tumor cells upon combined treatment with GCS inhibi-
tors [15,34,35]. In ALL cells we showed enhanced cyto-
toxicity when combining PPMP with 4-HPR (in
agreement with O’Donnell et al. [1]) or DHS. However,
our SL profiles with combination treatments (PPMP
+DHS+4-HPR and PPMP+SAF+4-HPR) suggest that, in
contrast to previously reported data, cytotoxicity is not
likely to be related to Cer content.
Based on the pro-survival functions described for
dhSph-1P and especially for Sph-1P, as well as the pro-
apoptotic effect driven by Sph and Cer [36], inhibition
of SK seems a logical approach for increasing malignant
cell death. Wang et al.[8] showed for the first time that
4-HPR increases dhSph and dhSph-1P in colon adeno-
carcinoma (HT29), promyelocytic leukemia (HL-60),
and multidrug resistant ovarian carcinoma (NCI/ADR-
RES) cell lines. We have now shown that the 4-HPR-
induced dhSph-1P accumulation in T-ALL cells (CCRF-
CEM) is due to augmented dhSph phosphorylation.
Moreover, our results prove that, in 4-HPR-resistant cell
lines (R0.5-R10), not only dhSph, but also Sph phos-
phorylation is increased, suggesting higher SK activity,
which is in agreement with the results obtained by
Illuzzi et al. [17]. In addition, the observed cytotoxicity
of DHS, SAF, and SKI-II-based treatments supports the
use of SK inhibitors in both 4-HPR-sensitive and resis-
tant leukemia cell lines as previously suggested for ovar-
ian carcinoma cells [8]. DHS and SAF are known not
just as SL modulators, but also as protein kinase C
(PKC) inhibitors [37,38]. SKI-II has been described as a
selective sphingosine kinase inhibitor at concentrations
below 60 μM[ 3 9 ]w i t hin vivo antitumor activity [40].
The differential cytotoxicity achieved by SAF and SKI-II
in Figure 8B-C could be due to the non-specific kinase
inhibition driven by SAF. In fact, our trials to mimic
PKC inhibition with a pharmacological approach con-
firmed the susceptibility of ALL cell lines to PKC inhibi-
tion (unpublished observation). Nevertheless, the data
clearly show the role of sphingosine kinase in tumor cell
survival and support its inhibition as an important anti-
tumor strategy.
Regarding other therapeutic alternatives for 4-HPR-
resistant cells, data from Appierto et al. [6] show no
cross-resistance to the synthetic retinoic CD437. In
addition, cells resistant to 4-HPR are sensitive to the 4-
HPR metabolite 4-oxo-4HPR [41]. Interestingly, other
studies reported that CD437-resistant leukemia and
ovarian carcinoma cell lines retained sensitivity to 4-
HPR [42,43], suggesting specific (vs. general) resistance
against retinoids. Our data on cisplatin, paclitaxel, adria-
mycin, UV radiation, and H2O2 in Figure 2 indicate a
lack of major cross-resistance. All of these agents have
been described to act, among other pathways, by
increasing endogenous Cer [44-48]. Therefore, our
results could be interpreted as a lack of cross-resistance
against Cer-increasing agents. The possible implication
of Cer must be taken with caution because a) all of
these insults have been described to increase ROS
Apraiz et al. BMC Cancer 2011, 11:477
http://www.biomedcentral.com/1471-2407/11/477
Page 10 of 13production [49-52], b) most studies have been per-
formed by [
3H]palmitic acid labeling or DAG kinase
plus TLC separation, which do not distinguish between
Cer and dhCer, and c) we recently described that oxida-
tive stress leads to dhCer, and not Cer, accumulation
[53].
Conclusions
In conclusion, development of the first 4-HPR-resistant
ALL cell lines has revealed that observed alterations in
the endogenous SL pattern are reversible and can be
dissociated from the resistance phenotype in leukemia.
Moreover, sensitivity of 4-HPR-resistant ALL cells to SL
modulating treatments was comparable to the sensitivity
observed in parental sensitive leukemia cells. We have
also shown that 4-HPR resistance does not induce
cross-resistance to other clinically applied drugs, provid-
ing feasible solutions for 4-HPR-resistant ALL
leukemias.
Additional material
Additional file 1: Comparative cellular proliferation of resistant cells
after drug withdrawal. CCRF-CEM, R10, and R10 long WD cells (1.5 ×
10
6 cells/cell line) were incubated for 15 min in CFSE-containing pre-
warmed PBS (0.36 μM, CO2 incubator). The PBS was replaced by FBS-
supplemented culture medium for 30 min. A total of 0.5 × 10
6 cells/cell
line were fixed with 2% paraformaldehyde-containing PBS and stored at
4°C to use them as parental (P) cells. A similar amount of cells was fixed
after 24 h and 48 h incubation. All samples were washed with PBS prior
to measuring fluorescence (excitation 485 nm and emission 530 nm) by
flow cytometry (Beckman Coulter Gallios; General Research Services
SGIker of the UPV/EHU (http://www.ikerkuntza.ehu.es/p273-sgikerhm/en/).
Generations (G) were determined using the ModFit LT™™ software.
Additional file 2: Toxicity profiles after combination of 4-HPR with
other SL modulators. CCRF-CEM cells were co-treated with 4-HPR (1-3
μM) and DHS (unnatural dhSph analogue) or PPMP (glucosylceramide
synthase inhibitor) for 24 h and viability estimated by metabolic activity
(XTT assay). Data are average ± SD of at least three independent
experiments performed in quadruplicate (n ≥ 12); *P < 0.05,**P < 0.01;
ANOVA plus Tamhane or Bonferroni post-hoc test.
Additional file 3: Effect of 4-HPR and other SL modulators on the
cellular SL pattern: TOTALdhCer and TOTALCer. 4-HPR sensitive ALL
cells (CCRF-CEM and Jurkat) were incubated for 2 h or 6 h with 4-HPR (1
μM), PPMP (10 μM), DHS (5 μM), and/or SAF (4 μM) and the SL level
determined. Complex treatments refer to 4-HPR+PPMP with either DHS
or SAF. Data are average ± SD of an experiment performed in duplicate.
Additional file 4: Effect of 4-HPR and other SL modulators on the
cellular SL pattern: TOTAL GluCer and TOTAL LactCer. 4-HPR-
sensitive ALL cells (CCRF-CEM and Jurkat) were incubated for 2 h or 6 h
with 4-HPR (1 μM), PPMP (10 μM), DHS (5 μM), and/or SAF (4 μM) and SL
levels determined. Complex treatments refer to 4-HPR+PPMP with either
DHS or SAF. Data are average ± SD of an experiment performed in
duplicate.
Additional file 5: Effect of 4-HPR and other SL modulators on the
cellular SL pattern: dhSph and Sph. 4-HPR-sensitive ALL cells (CCRF-
CEM and Jurkat) were incubated for 2 h or 6 h with 4-HPR (1 μM), PPMP
(10 μM), DHS (5 μM), and/or SAF (4 μM) and SL levels determined.
Complex treatments refer to 4-HPR+PPMP with either DHS or SAF. Data
are average ± SD of an experiment performed in duplicate.
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